AbbVie (ABBV) Inventory (2012 - 2026)

AbbVie (ABBV) has reported Inventory for 15 consecutive years, with $5.1 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Inventory rose 3.37% year-over-year to $5.1 billion in Q2 2026; TTM through Jun 2026 was $5.1 billion, a 3.37% increase from a year earlier, with the FY2025 full-year figure at $5.0 billion, up 18.42% from the prior year.
• Inventory was $5.1 billion for Q2 2026 at AbbVie, up from $5.0 billion in the prior quarter.
• Over five years, Inventory peaked at $5.1 billion in Q2 2026 and troughed at $3.2 billion in Q3 2022.
• A 5-year average of $4.2 billion and a median of $4.2 billion in 2024 frame the typical range for Inventory.
• Across the five-year window, Inventory gained 0.3% in 2022 and gained 25.5% in 2023, its largest moves.
• Over 5 years, Inventory stood at $3.6 billion in 2022, then grew by 14.53% to $4.1 billion in 2023, then climbed by 2.0% to $4.2 billion in 2024, then rose by 18.42% to $5.0 billion in 2025, then rose by 3.55% to $5.1 billion in 2026.
• The last three Inventory figures came in at $5.1 billion (Q2 2026), $5.0 billion (Q1 2026), and $5.0 billion (Q4 2025), per Business Quant data.